Lucid Diagnostics (LUCD) to Release Quarterly Earnings on Wednesday

Key Points

• Lucid Diagnostics is expected to announce its Q2 2025 earnings on August 13th, projecting earnings of ($0.09) per share and revenue of $1.15 million.
• The company's stock opened at $1.00, with a market cap of $108.19 million and a 12-month trading range between $0.73 and $1.80.
• Analyst ratings reflect mixed sentiment with one "sell," four "buy," and one "strong buy," leading to a consensus rating of "Moderate Buy" and a consensus price target of $3.55.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $1.15 million for the quarter.

Lucid Diagnostics Stock Up 1.6%

Shares of Lucid Diagnostics stock traded up $0.02 during trading on Friday, reaching $1.00. 465,665 shares of the company were exchanged, compared to its average volume of 898,538. Lucid Diagnostics has a twelve month low of $0.73 and a twelve month high of $1.80. The business has a 50-day moving average price of $1.15 and a 200-day moving average price of $1.26. The firm has a market capitalization of $107.82 million, a price-to-earnings ratio of -0.74 and a beta of 1.21.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LUCD shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $2.00 target price on shares of Lucid Diagnostics in a research note on Thursday, May 15th. Wall Street Zen lowered Lucid Diagnostics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Ascendiant Capital Markets upped their price objective on Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a research note on Friday, June 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Wednesday, July 16th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $3.55.

Institutional Investors Weigh In On Lucid Diagnostics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LUCD. Geode Capital Management LLC boosted its holdings in shares of Lucid Diagnostics by 420.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company's stock valued at $1,814,000 after acquiring an additional 1,274,194 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Lucid Diagnostics by 35.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company's stock valued at $129,000 after buying an additional 22,727 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics in the 1st quarter valued at about $39,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.